|
|
| Line 22: |
Line 22: |
| == The Elusiveness of OspA == | | == The Elusiveness of OspA == |
|
| |
|
| == References == | | <ref name=art3>PMID:11183781</ref> |
| | <ref name=art4>PMID:18097481</ref> |
|
| |
|
| 1. Burgdorfer W, Barbour A, Hayes S, Benach J, Grundwaldt E, and Davis J. 1982. Lyme Disease–A Tick-Borne Spirochetosis? Science. 216(4): 1317-1919.
| | ==Additional Resources== |
| | [http://www.wadsworth.org/databank/borreli.htm Wadsworth Center: NYS Department of Health] |
|
| |
|
| 2. Wormser GP, Dattwyler RJ, Shapiro ED, et al. (November 2006). "The clinical assessment, treatment, and prevention of Lyme disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America". Clin. Infect. Dis. 43 (9): 1089–134.
| | [http://www.cdc.gov/lyme/ CDC: Lyme Disease] |
|
| |
|
| 3. Ding W, Huang X, Yang X, Dunn J, Luft B, Koide S, and Lawson C. 2000. Structural Identification of a Key Prospective B-cell Epitope in Lyme Disease Antigen OspA. Journal of Molecular Biology. 302(5): 1153-1164.
| | ==References== |
|
| |
|
| 4. Rupprecht T, Koedel U, Fingerle V, and Pfister H. 2008. The Pathogenesis of Lyme Neurborreliosis: From Infection to Inflammation. Molecular Medicine. 14 (3): 205-212.
| | <references /> |